synthetic peptide is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-03-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Early interest in AOD-9604 centered on whether a fragment of human growth hormone could influence fat metabolism without the broader effects of the full hormone. Cell and animal studies reported changes in fat storage and breakdown. Human trials followed, but the results were not strong enough to secure regulatory approval. The compound remains available for laboratory research, and its clinical potential is still described as uncertain. Studies continue to examine its activity and safety profile.
AOD-9604 is a synthetic peptide that corresponds to a short section of human growth hormone. It is commonly identified as hGH fragment 176-191 because its sequence matches residues at the C-terminal end of the hormone. The molecule contains sixteen amino acids and is made by solid-phase peptide synthesis. Researchers study it for metabolic effects rather than for the growth-promoting actions associated with full human growth hormone. Its small size distinguishes it from the complete 191-amino-acid hormone.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
Povidone-iodine has found application in the field of nanomaterials. A wound-healing application has been developed which employs a mat of single wall carbon nanotubes (SWNTs) coated in a monolayer of povidone-iodine. Research has previously found that the polymer polyvinylpyrrolidone (PVP, povidone) can coil around individual carbon nanotubes to make them water-soluble.
Plastic (high-density polyethylene) Composite: steel and plastic Carbon steel Stainless steel (304 and 316/316L SS grades) Some IBC engineering models are foldable (collapsible) for space-saving breakdown following use.
The R1 plasmid is a plasmid that was first isolated from Salmonella paratyphi bacteria in 1963. It is a short plasmid, composed of 97,566 nucleotides and 120 genes, that belongs to the IncFII plasmid group. There are about one to two copies of the R1 plasmid per chromosome. The R1 plasmid imparts multi-drug antibiotic resistance to its host bacteria. The "R" in "R1" stands for "resistance", and the R1 plasmid contains resistance factors, or R factors, giving it the power to resist certain antibiotics. It's known as a "low copy" plasmid, meaning that it exists in relatively few copies in any given bacteria. This characteristic allows the R1 plasmid to have an efficient plasmid stabilization system, that aids in stabilizing medium copy number plasmids. R1 must rely on a "Type II" segregation system. This plasmid system ensures that at least one copy is contained in each daughter cell after cell division.
== Classification == A seroma contains serous fluid. This is composed of blood plasma that has seeped out of ruptured small blood vessels and the inflammatory fluid produced by injured and dying cells. Seromas are different from hematomas, which contain red blood cells, and abscesses, which contain pus and result from an infection. Serous fluid is also different from lymph.
== Awards == 1998–2000, Basil O'Connor Scholar, March of Dimes Birth Defects Foundation 1998–2000, Beckman Young Investigators Award, Arnold and Mabel Beckman Foundation 1998–2001, New Investigator in the Pharmacological Sciences, Burroughs Wellcome Fund 2007, William E.M. Lands Lectureship, University of Michigan Medical School 2013, Fellow, American Association for the Advancement of Science 2016, ASBMB Award for Exemplary Contributions to Education, American Society for Biochemistry and Molecular Biology 2020, Mary Swartz Rose Senior Investigator Award, American Society for Nutrition
Sources: en.wikipedia.org
Opioids by mouth, including both weak opioids such as tramadol and stronger opioids, are also often prescribed. Their appropriateness is uncertain, and opioids are often recommended only when first-line therapies have failed or are contraindicated. This is due to their small benefit and relatively large risk of side effects. The use of tramadol likely does not improve pain or physical function and likely increases the incidence of adverse side effects. Oral steroids are not recommended in the treatment of osteoarthritis. Use of the antibiotic doxycycline orally for treating osteoarthritis is not associated with clinical improvements in function or joint pain and long term use is associated with a high risk of side effects. A 2018 meta-analysis found that oral collagen supplementation for the treatment of osteoarthritis reduces stiffness, but does not improve pain and functional limitation.
== National variants == Similar meat and pastry recipes include the Czech klobásník, the Belgian worstenbroodje, the Dutch saucijzenbroodje, the German Münsterländer Wurstbrötchen and sausage bread in the United States. Hong Kong has developed its own style of sausage roll. Instead of having sausage meat wrapped in puff pastry like the traditional Western style, the Hong Kong style "sausage bun" (Chinese: 腸仔包) consists of a sausage wrapped inside a soft milk bread style bun.
Immunotherapy developed in the 1970s following the discovery of the structure of antibodies and the development of hybridoma technology, which provided the first reliable source of monoclonal antibodies. These advances allowed for the specific targeting of tumors both in vitro and in vivo. Initial research on malignant neoplasms found mAb therapy of limited and generally short-lived success with blood malignancies. Treatment also had to be tailored to each individual patient, which was impracticable in routine clinical settings. Four major antibody types that have been developed are murine, chimeric, humanised and human. Antibodies of each type are distinguished by suffixes on their name.
== Methods == Bisulfite sequencing applies routine sequencing methods on bisulfite-treated genomic DNA to determine methylation status at CpG dinucleotides. Other non-sequencing strategies are also employed to interrogate the methylation at specific loci or at a genome-wide level. All strategies assume that bisulfite-induced conversion of unmethylated cytosines to uracil is complete, and this serves as the basis of all subsequent techniques. Ideally, the method used would determine the methylation status separately for each allele. Alternative methods to bisulfite sequencing include Combined Bisulphite Restriction Analysis and methylated DNA immunoprecipitation (MeDIP). Methodologies to analyze bisulfite-treated DNA are continuously being developed. To summarize these rapidly evolving methodologies, numerous review articles have been written. The methodologies can be generally divided into strategies based on methylation-specific PCR (MSP) (Figure 4), and strategies employing polymerase chain reaction (PCR) performed under non-methylation-specific conditions (Figure 3). Microarray-based methods use PCR based on non-methylation-specific conditions also.
As enologists began better understanding the science of fermentation, nitrogen was identified as a principal nutrient and winemakers as early as the 1900s began adding ammonium salts to their must. Urea was also used as an early nitrogen supplement but research linking it to the development of ethyl carbamate has led to its banning in many countries, including the United States since 1990. There are many types of nitrogen supplements available for winemakers to use. Most of them are complex formulations that include nitrogen (from either amino acids or ammonium salts) along with vitamins, minerals and other growth factors and sold under brand names like Go-Ferm, Superfood, Fermaid K (the later two also containing some DAP). Amino acids can be added directly to the must though as of 2010 only glycine is permitted to be added to must in the United States.
Sources: en.wikipedia.org
Bergamot essential oil (pronounced ), is a cold-pressed essential oil produced by cells inside the rind of a bergamot orange fruit. It is a common flavouring and top note in perfumes. The scent of bergamot essential oil is similar to a sweet light orange peel oil with a floral note.
Recently, an efficient stepwise solid-phase synthesis of RANTES (24-91) was published. RANTES is a major HIV-suppressive factor produced by CD8+ T Cells. The serine protease CD26/dipeptidyl-peptidase IV (CD26/DPP IV) induces a NH2-terminal truncation from RANTES (1-91) to RANTES(24-91), which inhibits the infection of monocytes by an M-tropic HIV-1 strain The 68 amino acid of RANTES(24-91) has a high propensity to aggregate. The method combines the advantages of the PEG-based ChemMatrix resin and pseudoproline dipeptides. Direct coupling to pseudoproline monomer. Senko and his colleagues were the first to confirm the effectiveness of pseudoproline derivatives of individual, single residues in polypeptide synthesis. According to literature, the conversion of Ser(ΨPro) was excellent, however the Thr(ΨPro) varied in a wide range. The acylation of Pseudoproline monomer depended also on the chemical nature of the acylating residue. Manne and his colleagues successfully synthesized a human Growth Hormone (hGH)-derived polypeptide that was previously challenging to access, using Ser(ΨPro), while JR10 utilized Thr(ΨPro). Building upon Senko et al.'s work, Szaniszló and co-workers have recently improved the acylating efficiency of Thr(ΨPro) and incorporated it into their continuous flow peptide synthesizer.
To enforce the amendment, Congress passed the National Prohibition Act, also known as the Volstead Act. The Prohibition Bureau Narcotics Division, which enforced the Harrison Act, was overseen by Levi G. Nutt, the 1st narcotics commissioner of the United States. By the 1930s, the policy was seen as a failure: production and consumption of alcohol persisted, organized crime flourished in the alcohol black market, and tax revenue, particularly needed after the start of the Great Depression in 1929, was lost. Prohibition was repealed by passage of the 21st Amendment in 1933, with President Franklin D. Roosevelt (1933–1945) asking Americans not to abuse "this return to personal freedom." In 1922, the Narcotic Drugs Import and Export Act broadened federal regulation of opiates and coca products by prohibiting import and export for non-medical use, and established the Federal Narcotics Control Board (FNCB) to administrate.
exenatide (brand names Byetta and Bydureon, manufactured by AstraZeneca), approved 2005/2012, discontinued in 2024 albiglutide (Tanzeum, manufactured by GSK), approved in 2014, discontinued in 2017 lixisenatide (Lyxumia in Europe, Adlyxin in the United States, manufactured by Sanofi), approved in 2016, discontinued in 2023
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.